Capmatinib product name and manufacturer introduction

Capmatinib trade nameTabrecta is a precision targeted drug developed and produced by Novartis, the world's leading multinational pharmaceutical company. The drug is mainly targeted at patients with advanced or metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. Tabrecta is the first and only oral MET inhibitor approved by the FDA specifically for the treatment of this type of gene-mutated lung cancer. It has clear molecular targets and clinical value. As a global innovative pharmaceutical company with deep experience in oncology, cardiovascular, neurological diseases and other fields, Novartis has been committed to developing precision medicine drugs and promoting the development of personalized treatment.

Tabrecta's approval was based on data from the clinical trial GEOMETRY mono-1, in which capmatinib showed good therapeutic response and tolerability in patients with MET-mutated NSCLC. The emergence of this targeted therapy has brought new hope to the MET mutation patient group who had extremely limited treatment options in the past. The medicine is in the form of oral tablets, which is convenient for patients to take at home for a long time and helps improve compliance. In terms of composition, capmatinib is a highly selective MET tyrosine kinase inhibitor that can effectively block the abnormal activation of the MET signaling pathway, thereby inhibiting the growth and metastasis of cancer cells.

Novartis is also very active inTabrecta’s global layout. It is not only the first to be launched in the United States, but has also applied for approval in many countries and regions. However, the drug has not yet been officially launched in mainland China. Because the target of this drug is relatively specific, accurate genetic testing must be performed to confirm whether the patient carries the MET exon 14 skipping mutation before use. In addition, Novartis is also continuing to conduct research on expanding related indications, including MET-amplified NSCLC and other solid tumors, laying the foundation for future application in a wider range of people.

Reference materials:https://www.drugs.com/mtm/capmatinib.html